Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 1, 2010, Pages 65-71

  Wang, J Y ^a   Wang, J T ^a   Tsai, T H ^a   Hsu, C L ^a   Yu, C J ^a   Hsueh, P R ^b   Lee, L N ^a,b   Yang, P C ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Moxifloxacin; Prospective clinical trial; Taiwan; Time to culture conversion; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; ADULT; ARTICLE; BLURRED VISION; CALCULATION; CONTROLLED STUDY; DIZZINESS; DRUG FATALITY; FEMALE; GASTROINTESTINAL SYMPTOM; GOUT; HUMAN; HYPERURICEMIA; LIVER FUNCTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RASH; SIDE EFFECT; SPUTUM ANALYSIS; SPUTUM CULTURE; THROMBOCYTOPENIA; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING;

ADULT; AGED; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUINOLINES; SPUTUM; TAIWAN; TIME FACTORS; TUBERCULOSIS, PULMONARY;

EID: 76149124232     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Abal A T, Jayakrishnan B, Parwer S, El Shamy A, Abahussain E, Sharma P N. Effect of cigarette smoking on sputum smear conversion in adults with active pulmonary tuberculosis. Respir Med 2005; 99: 415-420.
2. Gopi P G, Chandrasekaran V, Subramani R, et al. Association of conversion and cure with initial smear grading among new smear-positive pulmonary tuberculosis patients treated with Category I regimen. Indian J Med Res 2006; 123: 807-814.
3. Lienhardt C, Manneh K, Bouchier V, Lahai G, Milligan P J, McAdam K P. Factors determining the outcome of treatment of adult smear-positive tuberculosis cases in The Gambia. Int J Tuberc Lung Dis 1998; 2: 712-718.
4. Ramarokoto H, Randriamiharisoa H, Rakotoarisaonina A, et al. Bacteriological follow-up of tuberculosis treatment: a comparative study of smear microscopy and culture results at the second month of treatment. Int J Tuberc Lung Dis 2002; 6: 909-912.
5. Rieder H L. Sputum smear conversion during directly observed treatment for tuberculosis. Tubercle Lung Dis 1996; 77: 124-129.
6. Singla R, Osman M M, Khan N, Al-Sharif N, Al-Sayegh M O, Shaikh M A. Factors predicting persistent sputum smear positivity among pulmonary tuberculosis patients 2 months after treatment. Int J Tuberc Lung Dis 2003; 7: 58-64.
7. Bozeman L, Burman W, Metchock B, Welch L, Weiner M. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis 2005; 40: 386-391.
8. Gillespie S H, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 1999; 44: 393-395.
9. Wang J Y, Hsueh P R, Jan I S, et al. Empiric treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with poor prognosis in endemic area. Thorax 2006; 63: 903-908.
10. Moadebi S, Harder C K, Fitzgerald M J, Elwood K R, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007; 67: 2077-2099.
11. Nuermberger E L, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004; 169: 421-426.
12. Johnson J L, Hadad D J, Boom W H, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10: 605-612.
13. Burman W J, Goldberg S, Johnson J L, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 331-338.
14. Dorman S E, Johnson J L, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180: 273-280.
15. Conde M B, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009; 373: 1183-1189.
16. Rustomjee R, Lienhardt C, Kanyok T, et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12: 128-138.
17. Salaniponi F M, Christensen J J, Gausi F, Kwanjana J J, Harries A D. Sputum smear status at two months and subsequent treatment outcome in new patients with smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis 1999; 3: 1047-1048.
18. Pfyffer G E, Brown-Elliott B A, Wallace R J J. Mycobacterium. In: Murray P R, Baron E J, Jorgensen J H, Pfaller M A, Yolken R H, eds. Manual of clinical microbiology. 6th ed. Washington DC, USA: American Society for Microbiology, 2005: pp 532-559.
19. National Committee of Clinical Laboratory Standards. Susceptibility testing of mycobacteria, Nocardiae, and other aerobic Actinomycetes: approved standards. Wayne, PA, USA: NCCLS, 2003.
20. Centers for Disease Control and Prevention. Treatment of tuberculosis. MMWR 2003; 52: 1-77.
21. el-Sadr W M, Perlman D C, Matts J P, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beim Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis 1998; 26: 1148-1158.
22. Jindani A, Aber V R, Edwards E A, Mitchison D A. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121: 939-949.
23. Mitchison D A. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000; 4: 796-806.
24. Connolly L E, Edelstein P H, Ramakrishnan L. Why is long-term therapy required to cure tuberculosis? PLoS Med 2007; 4: e120.
25. Wang J Y, Lee L N, Hsueh P R. Factors changing the manifestation of pulmonary tuberculosis. Int J Tuberc Lung Dis 2005; 9: 777-783.
26. Wang J Y, Hsueh P R, Jan I S, et al. The effect of smoking on tuberculosis: different patterns and poorer outcomes. Int J Tuberc Lung Dis 2007; 11: 143-149.
27. Pande J N, Singh S P, Khilnani G C, Khilnani S, Tandon R K. Risk factors for hepatotoxicity from anti-tuberculosis drugs: a case-control study. Thorax 1996; 51: 132-136.
28. Ormerod L P, Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tubercle Lung Dis 1996; 77: 37-42.
29. Quantrill S J, Woodhead M A, Bell C E, Hardy C C, Hutchison A J, Gokal R. Side-effects of antituberculosis drug treatment in patients with chronic renal failure. Eur Respir J 2002; 20: 440-443.
30. Gulbay B E, Gurkan O U, Yildiz O A, et al. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med 2006; 100: 1834-1842.
31. Steele M A, Burk R F, DesPrez R M. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99: 465-471.